Clinical trials
Not yet recruiting Lymphoma, T-Cell, Peripheral trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
21 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2023 | 1 |
| 2024 | 5 |
| 2025 | 7 |
| 2026 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Not yet recruiting | 21 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ruijin Hospital | 7 |
| Sun Yat-sen University | 2 |
| Boryung Pharmaceutical Co., Ltd | 1 |
| Boston Immune Technologies and Therapeutics | 1 |
| Evopoint Biosciences Inc. | 1 |
| Great Novel Therapeutics Biotech & Medicals Corporation | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| Peking University People's Hospital | 1 |
| Shanghai Jiao Tong University School of Medicine | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, T-Cell, Peripheral | 21 |
| Recurrence | 3 |
| Lymphoma, Large B-Cell, Diffuse | 2 |
| Lymphoma, Large-Cell, Anaplastic | 2 |
| Hodgkin Disease | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Lymphoma, B-Cell, Marginal Zone | 1 |
| Lymphoma, Follicular | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Lymphoma, T-Cell | 1 |
Trials
Showing 26 to 21 of 21. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.